Needle-free connectors (NFCs) – they’ve come a long way. They can be easily overlooked; however, NFCs are a constant touchpoint in the Vascular Access Device (VAD) system and remain the vascular access catheters microbial gatekeeper. Originally designed to improve the safety of healthcare workers by reducing needlestick injuries, opinions on these devices have shifted, with the latest evidence pointing to how these devices may aid in mitigating catheter related complications such as central line‒associated bloodstream infection (CLABSIs) and occlusions. There are many different designs of NFCs on the market, and many different functional claims, which can make it difficult to evaluate and confusing to choose the right NFC for your facility. Attention is required when it comes to their selection. This presentation distills current literature and guidelines, assesses the evidence, and highlights key design features and functionality to consider when selecting a NFC.
Michelle Landry is an accomplished Acute Care Pediatric Nurse Practitioner with over 10 years of clinical and research experience in infectious diseases, oncology, anesthesia, as well as other various settings. She holds a Master of Science in Nursing and a minor in genomics from the University of California, San Francisco (UCSF). She has a strong background in conducting CLABSI and bacterial genomic research and is passionate about improving patient outcomes and reducing healthcare-associated infections through evidence-based practice and innovation.
Ryan Callaghan is an accomplished professional in Global Marketing, Innovation, and Science, with extensive experience in developing and commercializing medical devices that meet global patient and customer needs. With over 15 years in healthcare, including roles as a senior scientist and extensive tenure in the medical device industry, Ryan brings deep insights to his current role leading BD’s IV Access Platform, specific to Needle-free Connectors. His career highlights include driving commercial efforts for BD’s cervical cancer diagnostic and IV therapy solutions, as well as holding a corporate role in BD Global Health, focused on deployment of market-appropriate solutions through public-private partnerships, original business models, and advocacy programs.